RAB29 (Gene)

Synonyms:ENTREZ:8934, HGNC:9789, MIM:603949, NM_001135662, NM_001135663, NM_001135664, NM_003929, NP_001129134, NP_001129135, NP_001129136, NP_003920, RAB29, RAB29, member RAS oncogene family, RAB7L, RAB7L1, XM_005245569, XM_005245570, XM_005245571, XM_006711605, XM_006711606, XM_017002748, XM_017002749, XM_017002750, XP_005245626, XP_005245627, XP_005245628, XP_006711668, XP_006711669, XP_016858237, XP_016858238, XP_016858239
Omim:OMIM:603949
Id:ENSG00000117280
Hgnc:HGNC:9789
Entrez:8934
Description:RAB29, member RAS oncogene family
Enables several functions, including dynein complex binding activity; guanyl ribonucleotide binding activity; and kinesin binding activity. Involved in several processes, including positive regulation of T cell receptor signaling pathway; positive regulation of receptor recycling; and toxin transport. Located in several cellular components, including Golgi apparatus; endosome; and vacuole. [provided by Alliance of Genome Resources, Apr 2022]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View RAB29's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with RAB29.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using RAB29.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for RAB29.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with RAB29.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.